Arcutis Biotherapeutics, Inc., a commercial-stage medical dermatology company, announced the appointment of David Topper as the new Chief Financial Officer (CFO), effective April 10, 2024. Topper succeeds John Smither, who had been serving as the interim CFO. Smither will assist with the transition until his resignation at the end of April. Topper brings over 40 years of experience in finance, investment management, and investment banking to Arcutis. His previous role was CFO at Inmagene Biopharmaceuticals, and he has held significant positions at General Atlantic, Frazier Life Sciences, J.P. Morgan, and Morgan Stanley. Topper's appointment is part of Arcutis' efforts to advance its commercial operations and position itself as a leader in medical dermatology. The company has entered into an employment agreement with Topper, which includes a base salary, performance bonus, and equity awards. The announcement was made via a press release on April 10, 2024, and was also reported in a Form 8-K filing with the SEC.

Arcutis Biotherapeutics, Inc., a commercial-stage medical dermatology company, announced the appointment of David Topper as the new Chief Financial Officer (CFO), effective April 10, 2024. Topper succeeds John Smither, who had been serving as the interim CFO. Smither will assist with the transition until his resignation at the end of April. Topper brings over 40 years of experience in finance, investment management, and investment banking to Arcutis. His previous role was CFO at Inmagene Biopharmaceuticals, and he has held significant positions at General Atlantic, Frazier Life Sciences, J.P. Morgan, and Morgan Stanley. Topper's appointment is part of Arcutis' efforts to advance its commercial operations and position itself as a leader in medical dermatology. The company has entered into an employment agreement with Topper, which includes a base salary, performance bonus, and equity awards. The announcement was made via a press release on April 10, 2024, and was also reported in a Form 8-K filing with the SEC.